NASDAQ : FLGT
Fulgent Genetics, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 21.68 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 596.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 530.77M |
| Enterprise Value | -10.97M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 27.52M |
| Shares Outstanding | 27.52M |
| Shares Change (YoY) | -1.51% |
| Shares Change (QoQ) | -9.31% |
| Owned by Insiders (%) | 39.31% |
| Owned by Institutions (%) | 57.50% |
| Float | 16.70M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.64 |
| Forward PS | 1.47 |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.34 |
| Quick Ratio | 4.56 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -960.73 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -8.11% |
| Return on Assets (ROA) | -6.30% |
| Return on Invested Capital (ROIC) | -15.10% |
| Return on Capital Employed (ROCE) | -11.33% |
| Weighted Average Cost of Capital (WACC) | 9.23% |
| Revenue Per Employee | $246,336 |
| Profits Per Employee | -$64,169 |
| Employee Count | 1,315 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -6.98M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -14.08% |
| 50-Day Moving Average | 20.76 |
| 200-Day Moving Average | 19.33 |
| Relative Strength Index (RSI) | 39.27 |
| Average Volume (20 Days) | 274,766 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.13M |
| Short Previous Month | 2.24M |
| Short % of Shares Out | 7.75% |
| Short % of Float | 12.77% |
| Short Ratio (days to cover) | 6.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 323.93M |
| Gross Profit | 115.26M |
| Operating Income | -115.29M |
| Pretax Income | -92.45M |
| Net Income | -84.38M |
| EBITDA | -89.46M |
| EBIT | -115.29M |
| Loss Per Share | -$2.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 257.03M |
| Total Debt | 9.60M |
| Net Cash | 541.75M |
| Net Cash Per Share | $19.69 |
| Equity (Book Value) | 995.99M |
| Book Value Per Share | 36.40 |
| Working Capital | 383.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -83.70M |
| Capital Expenditures | -20.09M |
| Depreciation & Amortization | 25.83M |
| Net Borrowing | -828,000 |
| Free Cash Flow | -103.79M |
| FCF Per Share | -$3.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | 35.58% |
| Operating Margin | -35.59% |
| Pretax Margin | -28.54% |
| Profit Margin | -26.05% |
| EBITDA Margin | -27.62% |
| EBIT Margin | -35.59% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.51% |
| Shareholder Yield | 1.51% |
| Earnings Yield | -14.56% |
| FCF Yield | -19.55% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 9.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.15 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |